FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969045494> ?p ?o ?g. }

• W1969045494 endingPage "607" @default.
• W1969045494 startingPage "606" @default.
• W1969045494 abstract "The painful or tender myopathy with elevated CPK due to statin drugs is well described and uncommon [1, 2]. Statin myopathy can also occur without elevated CPK or pain [3, 4] More common is a feeling of lack of energy in people taking these drugs. Since statins block mevalonate synthesis [5], they lower levels of ubiquinone, an essential compound for mitochondrial energy production, as well as lowering cholesterol. Thus, these people may truly lack energy. A few people who described lack of energy or having aged rapidly while on statins were advised to take ubiquinone (co-enzyme Q10, Co-Q10) while continuing the statin. Their energy level improved and they felt better. A randomized double-blind trial comparing 35 mg Co-Q10 bid with placebo bid was initiated after approval by the Weill Cornell IRB for patients on statins who felt lack of pep or energy since starting the statins and who did not have muscle pain, tenderness, or elevated CPK. By the time this trial started, most patients in my geographical area with these symptoms either stopped the statin or started Co-Q10 on their own, thus only three subjects were accrued in 1.5 years and the trial was stopped. The subjects’ ages were 68, 69, and 75. Plasma Co-Q10 levels were measured by sample pretreatment with 1,4-benzoquinone to change the reduced form of Co-Q10 to the oxidized form, precipitation with 1-propanol, and assayed on an HPLC with red-ox electrical chemical detection in the laboratory of Dr M.F. Beal [6, 7]. The Co-Q10 levels prior to study drug were 0.40, 0.35, and 0.36 µg ml−1 (normal values are 0.69 ± 0.04 [5] and 1.06 ± 0.33 [8]). Assessment of symptoms of fatigue at end of day, ability to climb stairs, and strength, as well as vital signs, heart rate after 3 min step test, serum lactate and cholesterol were measured before and after 2 weeks of study drug. Two subjects received placebo and one received Co-Q10. The results of these assessments were not different between the Co-Q10-treated and placebo-treated patients. At the 2-week visit, subjects were also asked how they felt. Both subjects taking placebo felt unchanged during the treatment period. The patient receiving Co-Q10 stated that several days after starting study drug, she felt more energetic and could now walk 20 (short New York City) blocks instead of the two blocks that tired her before. One of the placebo patients was given open Co-Q10, 35 mg bid, for an additional 2-week period. After 2 weeks, he claimed that he had more energy climbing stairs and was less tired than before. Statins lower levels of Co-Q10[5, 8], and our subjects had levels below published normal values. Statins also increase the lactate–pyruvate ratio suggesting decrease in mitochondrial oxidation [5]. Preliminary data suggest that Co-Q10 also acts on skeletal muscle to modify gene expression and change the composition of muscle fibres of vastus lateralus muscle from older people toward that of young people reversing the age-related change in skeletal muscle fibre composition [9]. Whether the level of fatigue and feeling of lack of energy in some people taking statins is related to skeletal muscle effects of these drugs is unknown. The results of this abbreviated randomized double-blind trial suggest it may be due to decreased ubiquinone levels due to effective statin inhibition of mevalonate synthesis. This would be an unintended adverse effect of the intended pharmacological action of the statin. People taking statins who describe lack of pep or energy may really lack energy because of a deficiency of ubiquinone. A definitive study of the value of ubiquinone replacement therapy for this subset of patients without pain but with fatigue and low Co-Q10 levels is highly desirable. Sponsored in part by Grant M01RR00047 from the General Clinical Research Centers Program of the Division of Research Resources of the NIH." @default.
• W1969045494 created "2016-06-24" @default.
• W1969045494 creator A5076827301 @default.
• W1969045494 date "2005-05-01" @default.
• W1969045494 modified "2023-09-25" @default.
• W1969045494 title "Statins, lack of energy and ubiquinone" @default.
• W1969045494 cites W2005365958 @default.
• W1969045494 cites W2007976725 @default.
• W1969045494 cites W2059078444 @default.
• W1969045494 cites W2070929323 @default.
• W1969045494 cites W2095119347 @default.
• W1969045494 cites W2095320268 @default.
• W1969045494 cites W2106936194 @default.
• W1969045494 cites W2109711778 @default.
• W1969045494 cites W2130873593 @default.
• W1969045494 doi "https://doi.org/10.1111/j.1365-2125.2005.02359.x" @default.
• W1969045494 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1884835" @default.
• W1969045494 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15842563" @default.
• W1969045494 hasPublicationYear "2005" @default.
• W1969045494 type Work @default.
• W1969045494 sameAs 1969045494 @default.
• W1969045494 citedByCount "10" @default.
• W1969045494 countsByYear W19690454942013 @default.
• W1969045494 countsByYear W19690454942019 @default.
• W1969045494 countsByYear W19690454942021 @default.
• W1969045494 countsByYear W19690454942022 @default.
• W1969045494 crossrefType "journal-article" @default.
• W1969045494 hasAuthorship W1969045494A5076827301 @default.
• W1969045494 hasBestOaLocation W19690454942 @default.
• W1969045494 hasConcept C126322002 @default.
• W1969045494 hasConcept C142724271 @default.
• W1969045494 hasConcept C1862650 @default.
• W1969045494 hasConcept C204787440 @default.
• W1969045494 hasConcept C27081682 @default.
• W1969045494 hasConcept C2776839432 @default.
• W1969045494 hasConcept C2777300911 @default.
• W1969045494 hasConcept C2778163477 @default.
• W1969045494 hasConcept C2779379848 @default.
• W1969045494 hasConcept C2779384338 @default.
• W1969045494 hasConcept C71924100 @default.
• W1969045494 hasConcept C98274493 @default.
• W1969045494 hasConceptScore W1969045494C126322002 @default.
• W1969045494 hasConceptScore W1969045494C142724271 @default.
• W1969045494 hasConceptScore W1969045494C1862650 @default.
• W1969045494 hasConceptScore W1969045494C204787440 @default.
• W1969045494 hasConceptScore W1969045494C27081682 @default.
• W1969045494 hasConceptScore W1969045494C2776839432 @default.
• W1969045494 hasConceptScore W1969045494C2777300911 @default.
• W1969045494 hasConceptScore W1969045494C2778163477 @default.
• W1969045494 hasConceptScore W1969045494C2779379848 @default.
• W1969045494 hasConceptScore W1969045494C2779384338 @default.
• W1969045494 hasConceptScore W1969045494C71924100 @default.
• W1969045494 hasConceptScore W1969045494C98274493 @default.
• W1969045494 hasIssue "5" @default.
• W1969045494 hasLocation W19690454941 @default.
• W1969045494 hasLocation W19690454942 @default.
• W1969045494 hasLocation W19690454943 @default.
• W1969045494 hasLocation W19690454944 @default.
• W1969045494 hasOpenAccess W1969045494 @default.
• W1969045494 hasPrimaryLocation W19690454941 @default.
• W1969045494 hasRelatedWork W1975178578 @default.
• W1969045494 hasRelatedWork W1976596999 @default.
• W1969045494 hasRelatedWork W1978481613 @default.
• W1969045494 hasRelatedWork W2003973731 @default.
• W1969045494 hasRelatedWork W2058490152 @default.
• W1969045494 hasRelatedWork W2066320566 @default.
• W1969045494 hasRelatedWork W2153775053 @default.
• W1969045494 hasRelatedWork W2565003573 @default.
• W1969045494 hasRelatedWork W2590650792 @default.
• W1969045494 hasRelatedWork W4292110673 @default.
• W1969045494 hasVolume "59" @default.
• W1969045494 isParatext "false" @default.
• W1969045494 isRetracted "false" @default.
• W1969045494 magId "1969045494" @default.
• W1969045494 workType "article" @default.